Laura Berner, JD, MBA

Laura Berner brings 20 years of experience across corporate and business development, investor relations, strategy and operations to her role as Chief Operating Officer of TRexBio. Prior to TRexBio, she was VP, Head of Business Development & Investor Relations at Myovant Sciences, where she led the execution of global partnering transactions for the commercialization of the company’s lead products (Myfembree® and Orgovyx®) and supported the company through multiple follow-on financings. Earlier in her career, she was a member of the Transactions team with Roche Pharma Partnering, responsible for leading transactions across the fields of oncology, immunology, neuroscience, infectious and rare diseases. She began her career as a corporate attorney first at Ropes & Gray LLP, and later in the Office of the General Counsel at Harvard University, advising on general corporate, business development and strategic partnering transactions. Ms. Berner serves as an independent director on the Board of Directors of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT).

Ms. Berner obtained her BA in biology  from Bryn Mawr College, her JD from Stanford Law School, and her MBA from Gies College of Business, University of Illinois Urbana-Champaign.